Ekso Bionics (EKSO) 10-Q 9 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 02, 2015
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Entity Registrant Name	EKSO BIONICS HOLDINGS, INC.
Entity Central Index Key	1,549,084
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015
Document Period End Date	Sep. 30, 2015
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		102,139,765

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 11,238	$ 25,190
Accounts receivable	2,185	1,549
Inventories, net	1,179	622
Prepaid expenses and other current assets	726	388
Deferred cost of revenue, current	1,920	1,551
Total current assets	17,248	29,300
Property and equipment, net	2,399	2,102
Deferred cost of revenue, non-current portion	2,424	2,017
Other assets	55	55
Total assets	22,126	33,474
Current liabilities:
Accounts payable	2,148	783
Accrued liabilities	2,190	2,378
Deferred revenues, current portion	3,839	3,412
Capital lease obligation, current	79	41
Total current liabilities	8,256	6,614
Deferred revenues, non-current portion	4,399	3,895
Other non-current liabilities	225	165
Total liabilities	$ 12,880	$ 10,674
Commitments and contingencies (Note 12)
Stockholders' equity:
Convertible Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2015 and December 31, 2014; none issued and outstanding at September 30, 2015 and December 31, 2014, respectively
Common stock, $0.001 par value; 500,000,000 shares authorized at September 30, 2015 and December 31, 2014; 102,371,591 and 101,621,358, shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	$ 102	$ 102
Additional paid-in capital	95,890	94,499
Accumulated deficit	(86,746)	(71,801)
Total stockholders' equity	9,246	22,800
Total liabilities and stockholders' equity	$ 22,126	$ 33,474

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Condensed Consolidated Balance Sheets [Abstract]
Convertible Preferred stock, par value per share	$ 0.001	$ 0.001
Convertible Preferred stock, shares authorized	10,000,000	10,000,000
Convertible Preferred stock, shares issued	0	0
Convertible Preferred stock, shares outstanding	0	0
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	102,371,591	101,621,358
Common stock, shares outstanding	102,371,591	101,621,358

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue
Medical devices	$ 1,095	$ 789	$ 3,128	$ 2,006
Engineering services	1,820	799	3,590	1,841
Total revenue	2,915	1,588	6,718	3,847
Cost of revenue
Medical devices	1,095	578	2,863	1,410
Engineering services	1,352	530	2,482	1,432
Total cost of revenue	2,447	1,108	5,345	2,842
Gross profit	468	480	1,373	1,005
Operating expenses
Sales and marketing	2,380	1,642	6,754	5,022
Research and development	1,713	1,096	4,438	2,564
General and administrative	1,556	1,474	5,090	5,354
Total operating expenses	5,649	4,212	16,282	12,940
Loss from operations	(5,181)	(3,732)	(14,909)	(11,935)
Other income (expense)
Interest expense	$ (4)	(3)	$ (10)	(433)
Gain (loss) on warrant liability		15,773		(1,206)
Interest income	$ 2	1	$ 9	4
Other expense, net	(2)	(15)	(35)	(44)
Total other income (expense), net	(4)	15,756	(36)	(1,679)
Net income (loss)	$ (5,185)	$ 12,024	$ (14,945)	$ (13,614)
Basic net income (loss) per share	$ (0.05)	$ 0.15	$ (0.15)	$ (0.18)
Weighted-average shares used in computing basic per share amounts	102,239,868	78,513,144	102,043,392	74,943,169
Diluted net income (loss) per share	$ (0.05)	$ (0.04)	$ (0.15)	$ (0.18)
Weighted-average shares used in computing diluted per share amounts	102,239,868	83,336,371	102,043,392	74,943,169

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities:
Net loss	$ (14,945)	$ (13,614)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	$ 653	535
Inventory allowance expense		21
Amortization of deferred rent	$ (28)	(27)
Amortization of debt discounts		191
Stock-based compensation expense	$ 1,259	810
Loss on increase in fair value of warrant liability		1,206
Changes in operating assets and liabilities:
Accounts receivable	$ (636)	(1,372)
Inventories	(379)	(161)
Prepaid expense and other assets	(338)	(80)
Deferred cost of revenue	(776)	(1,541)
Accounts payable	1,365	(422)
Accrued liabilities	(188)	(108)
Deferred revenues	931	2,266
Net cash used in operating activities	(13,082)	(12,296)
Investing activities:
Acquisition of property and equipment, net	$ (962)	(917)
Note receivable from stockholder		104
Net cash used in investing activities	$ (962)	(813)
Financing activities:
Principal payments on notes payable	(40)	$ (2,547)
Proceeds from exercise of stock options	80
Proceeds from exercise of common stock warrants	$ 52
Proceeds from issuance of common stock, net of issuance costs		$ 22,027
Net cash provided by financing activities	$ 92	19,480
Net increase (decrease) in cash	(13,952)	6,371
Cash at beginning of the period	25,190	805
Cash at end of the period	$ 11,238	$ 7,176

Organization

Organization	9 Months Ended
	Sep. 30, 2015
Organization [Abstract]
Organization	1. Organization Description of Business and Liquidity On January 15, 2014, a wholly-owned subsidiary of Ekso Bionics Holdings, Inc. named Ekso Acquisition Corp, merged with and into Ekso Bionics, Inc. (the “Merger”). Ekso Bionics, Inc. was the surviving corporation and became a wholly-owned subsidiary of Ekso Bionics Holdings, Inc. As a result of this transaction, Ekso Bionics Holdings, Inc. discontinued its pre-merger operations, acquired the business of Ekso Bionics, Inc. and continues the operations of Ekso Bionics, Inc. as a publicly traded company. See Note 3, The Merger, Offering and Other Related Transactions. Ekso Bionics, Inc. was incorporated in January 2005 in the State of Delaware. We are currently headquartered in Richmond, California. Our current medical device product, the Ekso GT, is a wearable bionic suit that provides individuals with stroke, spinal cord injuries and other lower-extremity paralysis or weakness the ability to stand and walk over ground with a full weight-bearing, reciprocal gait using a cane, crutches or a walker under the supervision of a physical therapist. Walking is achieved by the shifting of the user's body to activate sensors in the device that initiate steps. Battery-powered motors drive the legs, replacing deficient neuromuscular function. Sensors in the Ekso GT detect the level of motor control a user has, allowing the Ekso GT to provide that level of assist necessary for the user to complete his or her step. First-time users can expect to walk with aid from the device the first time they put on the Ekso exoskeleton (after passing an assessment), while an experienced user can transfer to or from their wheelchair and don or remove the Ekso in less than five minutes. Liquidity Largely as a result of significant research and development activities related to the development of our advanced technology and commercialization of this technology into our medical device business, we have incurred significant operating losses and negative cash flows from operations since inception. The Company has also recognized significant non-cash losses associated with the revaluation of certain securities, which have also contributed significantly to our accumulated deficit. As of September 30, 2015, we had an accumulated deficit of $ 86,746 11,238 25,190 13,082 12,296 1,550

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies and Estimates	9 Months Ended
	Sep. 30, 2015
Basis of Presentation and Summary of Significant Accounting Policies and Estimates [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies and Estimates	2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates There have been no material changes to our significant accounting policies as compared to those described in our Annual Report on Form 10-K for the year ended December 31, 2014. Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for the presentation of interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2014, has been derived from the audited consolidated financial statements at that date but does not include all disclosures required for the annual financial statements and should be read in conjunction with our audited consolidated financial statements and notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2014. Unless otherwise indicated, all dollar amounts included in these notes to the financial statements are in thousands. In management's opinion, the condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position at September 30, 2015, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year. The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates. Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable. Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. We review accounts receivable for collectability and provide an allowance for credit losses, as needed. We have not experienced any material losses related to accounts receivable as of September 30, 2015 and December 31, 2014. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. We do not enter into any foreign currency hedging agreements and are susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable. As of September 30, 2015, we had three customers with accounts receivable balances totaling 10% or more of our total accounts receivable ( 15 11 10 22 11 In the three months ended September 30, 2015, we had one customer with sales comprising 10% or more of our total customer sales ( 48 19 17 17 of our total customer sales ( 33 17 Common Stock Warrants We accounted for the common stock warrants issued in connection with our Merger and related private placement offering (see Note 3, The Merger, Offering and Other Related Transactions) Recent Accounting Pronouncements In July 2015, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2015-11 Simplifying the Measurement of Inventory. Under ASU 2015-11, inventory is to be measured at the lower of cost and net realizable value (“NRV”). NRV is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. In August 2015, the FASB issued an update, ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,

The Merger, Offering and Other

The Merger, Offering and Other Related Transactions	9 Months Ended
	Sep. 30, 2015
The Merger, Offering and Other Related Transactions [Abstract]
The Merger, Offering and Other Related Transactions	3. The Merger, Offering and Other Related Transactions Holdings was incorporated in the State of Nevada on January 30, 2012 as a distributor of medical supplies and equipment to municipalities, hospitals, pharmacies, care centers, and clinics in Chile. At the time of the Merger, Holdings was a “shell company” as defined in Rule 12b-2 of the Exchange Act. Holdings' fiscal year end was previously March 31 but was changed to December 31 in connection with the Merger. On January 15, 2014, Holdings and a newly formed wholly-owned subsidiary of Holdings, Ekso Acquisition Corp, (“Acquisition Sub”) entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Ekso Bionics. Under the Merger Agreement, Acquisition Sub merged with and into Ekso Bionics, with Ekso Bionics remaining as the surviving corporation and with the stockholders of Ekso Bionics exchanging all of their common stock, convertible preferred stock and warrants to purchase preferred stock issued and outstanding immediately prior to the closing of the Merger into an aggregate of 42,615,556 621,361 4,989,111 7,602,408 5,280,368 4,500,600 779,768 6.8 Upon the closing of the Merger, under the terms of a split-off agreement and a general release agreement, Holdings transferred all of its pre-Merger operating assets and liabilities to a newly formed wholly-owned special-purpose subsidiary (“Split-Off Subsidiary”), and transferred all of the outstanding shares of capital stock of Split-Off Subsidiary to two individuals who were the pre-Merger majority stockholders of Holdings and Holdings' former officers and sole director (the “Split-Off”), in consideration of and in exchange for (a) the surrender and cancellation of all shares of Holdings' common stock held by such individuals (which were cancelled and resumed the status of authorized but unissued shares of our common stock) and (b) certain representations, covenants and indemnities. Accounting for Reverse Merger Ekso Bionics, as the accounting acquirer, recorded the Merger as the issuance of stock for the net monetary assets of Holdings accompanied by a recapitalization. This accounting was identical to that resulting from a reverse merger, except that no goodwill or intangible assets were recorded. In filings with the SEC subsequent to the Merger, including this filing, the historical financial statements of Holdings before the Merger have been replaced with the historical financial statements of Ekso Bionics before the Merger. The Merger was intended to be treated as a tax-free exchange under Section 368(a) of the Internal Revenue Code of 1986, as amended. Retroactive Conversion of all Share and Per Share Amounts In accordance with reverse merger accounting guidance, amounts for Ekso Bionics' historical (pre-merger) common stock, preferred stock and warrants and options to purchase common stock, including share and per share amounts, have been retroactively adjusted using their respective exchange ratios in these financial statements unless otherwise disclosed. The conversion ratios were 1.5238 1.6290 1.9548 1.9548 Repayment of 2013 Bridge Note In November 2013, in anticipation of the Merger and related private placement offering, Ekso Bionics completed a private placement to accredited investors of $ 5,000 83 5,000,000 2,500,000 1.00 three Private Placement Offering Concurrently with the closing of the Merger and in contemplation of the Merger, the Company held a closing of a private placement offering (“PPO”) in which it sold 20,580,000 1.00 one 2.00 five 9,720,000 30,300,000 25,300 5,083 2,553 3,338 Investors in the Units have weighted average anti-dilution protection with respect to the shares of common stock included in the Units if within 24 months after the final closing of the PPO the Company issues additional shares of common stock or common stock equivalents (subject to customary exceptions, including but not limited to issuances of awards under the Company's 2014 Equity Incentive Plan) for consideration per share less than $1.00. The PPO warrants also had weighted average anti-dilution protection, subject to customary exceptions. In connection with the conversion of the 2013 Bridge Notes and the PPO, the placement agent for the PPO and its sub-agents were paid an aggregate commission of $ 3,030 3,030,000 five 1.00 Offer to Amend and Exercise In November 2014, the Company consummated an offer to amend and exercise its PPO Warrants at a temporarily reduced exercise price (“Offer to Amend and Exercise”). Pursuant to the Offer to Amend and Exercise, an aggregate of 22,755,500 2.00 1.00 In connection with the Offer to Amend and Exercise, the holders of a majority of the then outstanding PPO Warrants, Bridge Warrants, and Agent Warrants approved an amendment to remove the price-based anti-dilution provisions in those warrants (see Note 9, Warrants 2014 Equity Incentive Plan Before the Merger, the Board of Directors adopted, and the stockholders approved, the 2014 Equity Incentive Plan (“2014 Plan”), which provides for the issuance of incentive awards constituting up to 14,410,000 7,602,408 On the closing of the Merger, the Board granted to officers and directors options to purchase an aggregate of 2,300,000 Subsequent to the Merger, on June 10, 2015, the Board submitted to the stockholders and the stockholders approved and ratified an amendment of the 2014 Plan to increase the maximum number of shares of common stock that may be issued under the 2014 Plan by 11,590,000 26,000,000

Deferred Revenues

Deferred Revenues	9 Months Ended
	Sep. 30, 2015
Deferred Revenues [Abstract]
Deferred Revenues	4. Deferred Revenues In connection with our medical device sales and research services, we often receive cash payments before our earnings process is complete. In these instances, we record the payments as customer deposits until a device is shipped to the customer, or as customer advances in the case of research services until the earnings process is achieved. In both cases, the cash received is recorded as a component of deferred revenue. Revenue from our Ekso medical device sales is deferred and recognized over the maintenance period. Accordingly, at the time of shipment to the customer the amount billed is recorded as deferred revenue. Also, at the time of shipment, the related inventory is reclassified to deferred cost of revenue where it is amortized to cost of revenue over the same period as the related revenue. Deferred revenues and deferred cost of revenues consist of the following: September 30, December 31, 2015 2014 Customer deposits and advances $ 90 $ 105 Deferred Ekso medical device revenues 5,917 5,327 Deferred service and leasing revenues 2,231 1,875 Deferred revenues 8,238 7,307 Less current portion (3,839 ) (3,412 ) Deferred revenues, non-current $ 4,399 $ 3,895 Deferred Ekso medical device costs $ 4,344 $ 3,568 Less current portion (1,920 ) (1,551 ) Deferred cost of revenue, non-current $ 2,424 $ 2,017

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2015
Accrued Liabilities [Abstract]
Accrued Liabilities	5. Accrued Liabilities Accrued liabilities consist of the following: September 30, December 31, 2015 2014 Salaries, benefits and related expenses $ 1,687 $ 1,847 Professional fees 298 184 Warranty expense - 126 Taxes 46 46 Royalties - 50 Travel 15 76 All other 144 49 Total $ 2,190 $ 2,378

Capital Lease Obligation

Capital Lease Obligation	9 Months Ended
	Sep. 30, 2015
Capital Lease Obligation [Abstract]
Capital Lease Obligation	6. Capital Lease Obligation In 2012, the Company entered into a note agreement in connection with the lease for its Richmond, California facility. The note, for an aggregate principal of $ 200 7 4 May 31, 2017 166 4.7 3 July 1, 2020 169 13 Leasehold Improvement Capital Note Lease Total 2015 (remainder) $ 12 $ 10 $ 22 2016 48 42 90 2017 20 40 60 2018 - 37 37 2019 - 37 37 Thereafter - 22 22 Total minimum payments 80 188 268 Less: interest (5 ) (19 ) (24 ) Present value minimum payments 75 169 244 Less: current portion (44 ) (35 ) (79 ) Long-term portion of capital lease obligation $ 31 $ 134 $ 165

Operating Lease

Operating Lease	9 Months Ended
	Sep. 30, 2015
Operating Lease [Abstract]
Operating Lease	7. Operating Lease On November 29, 2011, the Company entered into an operating lease agreement for its headquarters and manufacturing facility in Richmond, California. The lease term commenced in March 2012 and expires in May 2017. The lease provides the Company with one option to renew for five Future minimum operating lease payments are as follows as of September 30, 2015: 2015 (remainder of year) $ 94 2016 375 2017 157 Total $ 626 Rent expense under the Company's operating leases was $ 86 86 258 257

Capitalization and Equity Struc

Capitalization and Equity Structure	9 Months Ended
	Sep. 30, 2015
Capitalization and Equity Structure [Abstract]
Capitalization and Equity Structure	8. Capitalization and Equity Structure The Company's authorized capital stock at September 30, 2015, consisted of 500,000,000 shares of common stock and 10,000,000 shares of preferred stock. At September 30, 2015, 102,371,591 shares of common stock were issued and outstanding, and no shares of preferred stock were issued and outstanding.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2015
Warrants [Abstract]
Warrants	9. Warrants As discussed in Note 3, The Merger, Offering and Other Related Transactions, 36,055,000 30,300,000 2.00 1.00 Due to the market price of the Company's common stock price exceeding the exercise price of the then outstanding warrants, the Company recorded a non-cash benefit of $ 15,773 1,206 The assumptions utilized in re-valuing the warrants were as follows as of September 30, 2014: Dividend yield – Risk-free interest rate 0.72 1.53 % Share price at final valuation 0.84 Expected term (in years) 2.30 4.30 Volatility 65 70 % Periodic rate 0.17 0.66 % Periods in the model 10 These warrants were amended in November 2014 to remove the price-based anti-dilution provision, among other things. Accordingly, the warrants are no longer recorded as a liability. Warrant activity for the nine month period ended September 30, 2015 is as follows: Balance Exercise Term Balance Name December 31, 2014 Price (Years) Exercised September 30, 2015 Placement agent warrants 3,030,000 $ 1.00 5 (48,700 ) 2,981,300 Bridge warrants 2,600,000 $ 1.00 3 2,600,000 PPO warrants 7,544,500 $ 2.00 5 7,544,500 Pre-Merger/PPO warrants* 621,361 $ 1.38 various (2,720 ) 618,641 Total 13,795,861 (51,420 ) 13,744,441 * The Pre-Merger/PPO warrants all expire on May 20, 2023

Stock-based Compensation Plans

Stock-based Compensation Plans and Awards	9 Months Ended
	Sep. 30, 2015
Stock-based Compensation Plans and Awards [Abstract]
Stock-based Compensation Plans and Awards	10. Stock-based Compensation Plans and Awards In January 2014, and prior to the Merger, the Board of Directors and a majority of the stockholders adopted the 2014 Plan that allowed for the issuance of 14,410,000 7,602,408 11,590,000 26,000,000 11,801,901 Under the terms of the 2014 Plan, the Board of Directors may award stock, options, or similar rights having either a fixed or variable price related to the fair market value of the shares and with an exercise or conversion privilege related to the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions, or any other security with the value derived from the value of the shares. Such awards include stock options, restricted stock, restricted stock units, stock appreciation rights and dividend equivalent rights. The Board of Directors may grant stock options under the 2014 Plan at a price of not less than 100 110 five ten four Equity-Based Payments to Non-Employees The following table summarizes information about the Company's stock options outstanding at September 30, 2015, and activity during the nine-month period then ended: Weighted- Average Stock Weighted- Remaining Aggregate Awards Average Contractual Intrinsic Outstanding Exercise Price Life (Years) Value Balance as of December 31, 2014 10,791,081 $ 0.79 Options granted 3,332,800 $ 1.40 Options exercised (1,067,806 ) $ 0.52 Options forfeited (128,888 ) $ 0.76 Options cancelled (104,813 ) $ 0.50 Balance as of September 30, 2015 12,822,374 $ 0.98 7.84 $ 4,154 Vested and expected to vest at September 30, 2015 11,850,532 $ 0.95 7.73 $ 4,098 Exercisable as of September 30, 2015 6,103,793 $ 0.66 6.51 $ 3,498 Of 846,576 368,993 As of September 30, 2015, total unrecognized compensation cost related to unvested stock options was $ 4,998 2.93 Three months ended September 30, Nine months ended September 30, 2015 2014 (1) 2015 2014 Dividend yield — — — — Risk-free interest rate 1.68 % — 1.41 2.50 % 1.74 2.61 % Expected term (in years) 6.08 — 6.08 10 6.08 10 Volatility 75.27 % — 73.21 75.27 % 65.66 66.46 % (1) No options were granted for the three months ended September 30, 2014. Total stock-based compensation expense related to options granted to employees and non-employees was included in the Condensed Consolidated Statements of Operations as follows: Three months ended September 30, Nine months ended September 30 , 2015 2014 2015 2014 Sales and marketing $ 147 $ 9 $ 440 $ 260 Research and development 133 36 295 125 General and administrative 187 72 524 425 $ 467 $ 117 $ 1,259 $ 810

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Taxes [Abstract]
Income Taxes	11. Income Taxes There were no

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Contingencies In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Company's condensed consolidated financial statements. Material Contracts The Company enters into various license, research collaboration and development agreements which provide for payments to the Company for government grants, fees, cost reimbursements typically with a markup, technology transfer and license fees, and royalty payments on sales. The Company has two license agreements to maintain exclusive rights to certain patents. Under these license agreements, the Company is required to pay 1 21 1 50 U.S. Food and Drug Administration Clearance The Company's Ekso GT robotic exoskeleton has been marketed in the United States as a Class I 510(k) exempt Powered Exercise Equipment device since February 2012. On June 26, 2014, the U.S. Food and Drug Administration (“FDA”) announced the creation of a new product classification for Powered Exoskeleton devices. On October 21, 2014, the FDA published the summary for the new Powered Exoskeleton classification and designated it as being Class II, which requires the clearance of a 510(k) notice. On October 21, 2014, concurrent with the FDA's publication of the reclassification of Powered Exoskeleton devices, the FDA issued the Company an “Untitled Letter” which informed the Company in writing of the agency's belief that this new product classification applied to our Ekso GT device. We filed a 510(k) notice for the Ekso robotic exoskeleton on December 24, 2014, which was accepted by the FDA for substantive review on July 29, 2015. The Company intends to continue marketing the Ekso robotic exoskeleton under its current Class I registration and listing with its current indications for use until 510(k) clearance is either granted or denied by the FDA or the Company is otherwise notified by the FDA to cease such activities. The Company believes that in situations where the class of a product has been elevated by the FDA, manufacturers are normally granted enforcement discretion by the FDA and given ample time to seek clearance at the new class level. Nonetheless, the FDA may not agree with our decision to continue marketing the device until a 510(k) notice is cleared. From the time of our submission to the date of this report, the FDA has not indicated or notified the Company that it disagrees with this decision. If the FDA disagrees with our decision, we may be required to cease marketing or to recall the products until we obtain clearance or approval, and we may be subject to regulatory fines or penalties. From September 2, 2015 to September 11, 2015, the Division of Bioresearch Monitoring Center for Devices and Radiological Health of the FDA conducted an inspection of the Company's facility in Richmond, California. At the conclusion of the inspection, the FDA issued a Form FDA 483 with four observations. These observations are inspectional and do not represent a final FDA determination of non-compliance. The observations pertain to informed consent requirements, reporting of adverse results and records maintenance. On October 2, 2015, the Company responded to the FDA. That response describes the corrective and preventive actions that we have implemented and continue to implement to address the FDA's concerns.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	9 Months Ended
	Sep. 30, 2015
Net Income (Loss) Per Share [Abstract]
Net Income (Loss) Per Share	13. Net Income (Loss) Per Share The following table sets forth the computation of basic and diluted net income (loss) per share: Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 Numerator: Net profit (loss) Basic $ (5,185 ) $ 12,024 $ (14,945 ) $ (13,614 ) Adjustment for change in fair value of warrant liability - (15,773 ) - - Diluted $ (5,185 ) $ (3,749 ) $ (14,945 ) $ (13,614 ) Denominator: Weighted-average common shares outstanding used in computing basic and diluted net income (loss) per share Basic 102,239,868 78,513,144 102,043,392 74,943,169 Dilutive effect of warrants - 750,653 - - Dilutive effect of stock options - 4,072,574 - - Diluted 102,239,868 83,336,371 102,043,392 74,943,169 Net income (loss) per share, basic $ (0.05 ) $ 0.15 $ (0.15 ) $ (0.18 ) Net income (loss per share, diluted $ (0.05 ) $ (0.04 ) $ (0.15 ) $ (0.18 ) The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented: Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 Options to purchase common stock 12,822,374 - 12,822,374 3,724,529 Warrants 13,744,441 - 13,744,441 8,407,084 Total common stock equivalents 26,566,815 - 26,566,815 12,131,613

Segment Disclosures

Segment Disclosures	9 Months Ended
	Sep. 30, 2015
Segment Disclosures [Abstract]
Segment Disclosures	14. Segment Disclosures The Company has two reportable segments, Engineering Services and Medical Devices. Engineering Services generates revenue principally from collaborative research and development service arrangements, technology license agreements, and government grants where the Company uses its robotics domain knowledge in bionic exoskeletons to bid on and procure contracts and grants from entities such as such as the National Science Foundation and the Defense Advanced Research Projects Agency. The Medical Devices segment designs, engineers, and manufactures exoskeletons for applications in the medical and military markets. The Company evaluates performance and allocates resources based on segment gross profit margin. The reportable segments are each managed separately because they serve distinct markets, and one segment provides a service and the other manufactures and distributes a unique product. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated. Segment reporting information is as follows: Engineering Medical Services Devices Total Three months ended September 30, 2015 Revenue $ 1,820 $ 1,095 $ 2,915 Cost of revenue 1,352 1,095 2,447 Gross profit $ 468 $ 0 $ 468 Three months ended September 30, 2014 Revenue $ 799 $ 789 $ 1,588 Cost of revenue 530 578 1,108 Gross profit $ 269 $ 211 $ 480 Nine months ended September 30, 2015 Revenue $ 3,590 $ 3,128 $ 6,718 Cost of revenue 2,482 2,863 5,345 Gross profit $ 1,108 $ 265 $ 1,373 Nine months ended September 30, 2014 Revenue $ 1,841 $ 2,006 $ 3,847 Cost of revenue 1,432 1,410 2,842 Gross profit $ 409 $ 596 $ 1,005 Geographic information for revenue based on location of customer is as follows: Three months e nded September 30, Nine months ended September 30, 2015 2014 2015 2014 North America $ 2,379 $ 1,271 $ 5,272 $ 3,102 Europe, Middle East, Asia 536 317 1,446 745 $ 2,915 $ 1,588 $ 6,718 $ 3,847

Basis of Presentation and Sum20

Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Policies)	9 Months Ended
	Sep. 30, 2015
Basis of Presentation and Summary of Significant Accounting Policies and Estimates [Abstract]
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for the presentation of interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2014, has been derived from the audited consolidated financial statements at that date but does not include all disclosures required for the annual financial statements and should be read in conjunction with our audited consolidated financial statements and notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2014. Unless otherwise indicated, all dollar amounts included in these notes to the financial statements are in thousands. In management's opinion, the condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position at September 30, 2015, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year. The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable. Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. We review accounts receivable for collectability and provide an allowance for credit losses, as needed. We have not experienced any material losses related to accounts receivable as of September 30, 2015 and December 31, 2014. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. We do not enter into any foreign currency hedging agreements and are susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable. As of September 30, 2015, we had three customers with accounts receivable balances totaling 10% or more of our total accounts receivable ( 15 11 10 22 11 In the three months ended September 30, 2015, we had one customer with sales comprising 10% or more of our total customer sales ( 48 19 17 17 of our total customer sales ( 33 17
Common Stock Warrants	Common Stock Warrants We accounted for the common stock warrants issued in connection with our Merger and related private placement offering (see Note 3, The Merger, Offering and Other Related Transactions)
Recent Accounting Pronouncements	Recent Accounting Pronouncements In July 2015, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2015-11 Simplifying the Measurement of Inventory. Under ASU 2015-11, inventory is to be measured at the lower of cost and net realizable value (“NRV”). NRV is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. In August 2015, the FASB issued an update, ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,

Deferred Revenues (Tables)

Deferred Revenues (Tables)	9 Months Ended
	Sep. 30, 2015
Deferred Revenues [Abstract]
Schedule of Customer Deposits, Advances, Deferred Revenues, and Deferred Unit Costs	September 30, December 31, 2015 2014 Customer deposits and advances $ 90 $ 105 Deferred Ekso medical device revenues 5,917 5,327 Deferred service and leasing revenues 2,231 1,875 Deferred revenues 8,238 7,307 Less current portion (3,839 ) (3,412 ) Deferred revenues, non-current $ 4,399 $ 3,895 Deferred Ekso medical device costs $ 4,344 $ 3,568 Less current portion (1,920 ) (1,551 ) Deferred cost of revenue, non-current $ 2,424 $ 2,017

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Accrued Liabilities [Abstract]
Schedule of Accrued Liabilities	September 30, December 31, 2015 2014 Salaries, benefits and related expenses $ 1,687 $ 1,847 Professional fees 298 184 Warranty expense - 126 Taxes 46 46 Royalties - 50 Travel 15 76 All other 144 49 Total $ 2,190 $ 2,378

Capital Lease Obligation (Table

Capital Lease Obligation (Tables)	9 Months Ended
	Sep. 30, 2015
Capital Lease Obligation [Abstract]
Schedule of future obligations under debt instruments	Leasehold Improvement Capital Note Lease Total 2015 (remainder) $ 12 $ 10 $ 22 2016 48 42 90 2017 20 40 60 2018 - 37 37 2019 - 37 37 Thereafter - 22 22 Total minimum payments 80 188 268 Less: interest (5 ) (19 ) (24 ) Present value minimum payments 75 169 244 Less: current portion (44 ) (35 ) (79 ) Long-term portion of capital lease obligation $ 31 $ 134 $ 165

Operating Lease (Tables)

Operating Lease (Tables)	9 Months Ended
	Sep. 30, 2015
Operating Lease [Abstract]
Schedule of Future Minimum Operating Lease Payments	2015 (remainder of year) $ 94 2016 375 2017 157 Total $ 626

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2015
Warrants [Abstract]
Schedule of assumption used in valuation	Dividend yield – Risk-free interest rate 0.72 1.53 % Share price at final valuation 0.84 Expected term (in years) 2.30 4.30 Volatility 65 70 % Periodic rate 0.17 0.66 % Periods in the model 10
Schedule of warrants activity	Balance Exercise Term Balance Name December 31, 2014 Price (Years) Exercised September 30, 2015 Placement agent warrants 3,030,000 $ 1.00 5 (48,700 ) 2,981,300 Bridge warrants 2,600,000 $ 1.00 3 2,600,000 PPO warrants 7,544,500 $ 2.00 5 7,544,500 Pre-Merger/PPO warrants* 621,361 $ 1.38 various (2,720 ) 618,641 Total 13,795,861 (51,420 ) 13,744,441

Stock-based Compensation Plan26

Stock-based Compensation Plans and Awards (Tables)	9 Months Ended
	Sep. 30, 2015
Stock-based Compensation Plans and Awards [Abstract]
Summary of Stock Option Activity	Weighted- Average Stock Weighted- Remaining Aggregate Awards Average Contractual Intrinsic Outstanding Exercise Price Life (Years) Value Balance as of December 31, 2014 10,791,081 $ 0.79 Options granted 3,332,800 $ 1.40 Options exercised (1,067,806 ) $ 0.52 Options forfeited (128,888 ) $ 0.76 Options cancelled (104,813 ) $ 0.50 Balance as of September 30, 2015 12,822,374 $ 0.98 7.84 $ 4,154 Vested and expected to vest at September 30, 2015 11,850,532 $ 0.95 7.73 $ 4,098 Exercisable as of September 30, 2015 6,103,793 $ 0.66 6.51 $ 3,498
Schedule of Fair Value Calculation Assumptions	Three months ended September 30, Nine months ended September 30, 2015 2014 (1) 2015 2014 Dividend yield — — — — Risk-free interest rate 1.68 % — 1.41 2.50 % 1.74 2.61 % Expected term (in years) 6.08 — 6.08 10 6.08 10 Volatility 75.27 % — 73.21 75.27 % 65.66 66.46 %
Allocation of Stock Option Compensation Expense	Three months ended September 30, Nine months ended September 30 , 2015 2014 2015 2014 Sales and marketing $ 147 $ 9 $ 440 $ 260 Research and development 133 36 295 125 General and administrative 187 72 524 425 $ 467 $ 117 $ 1,259 $ 810

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2015
Net Income (Loss) Per Share [Abstract]
Schedule of basic and diluted net income (loss) per share	Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 Numerator: Net profit (loss) Basic $ (5,185 ) $ 12,024 $ (14,945 ) $ (13,614 ) Adjustment for change in fair value of warrant liability - (15,773 ) - - Diluted $ (5,185 ) $ (3,749 ) $ (14,945 ) $ (13,614 ) Denominator: Weighted-average common shares outstanding used in computing basic and diluted net income (loss) per share Basic 102,239,868 78,513,144 102,043,392 74,943,169 Dilutive effect of warrants - 750,653 - - Dilutive effect of stock options - 4,072,574 - - Diluted 102,239,868 83,336,371 102,043,392 74,943,169 Net income (loss) per share, basic $ (0.05 ) $ 0.15 $ (0.15 ) $ (0.18 ) Net income (loss per share, diluted $ (0.05 ) $ (0.04 ) $ (0.15 ) $ (0.18 )
Schedule of Antidilutive Securities	Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 Options to purchase common stock 12,822,374 - 12,822,374 3,724,529 Warrants 13,744,441 - 13,744,441 8,407,084 Total common stock equivalents 26,566,815 - 26,566,815 12,131,613

Segment Disclosures (Tables)

Segment Disclosures (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Disclosures [Abstract]
Schedule of Segment Reporting Information	Engineering Medical Services Devices Total Three months ended September 30, 2015 Revenue $ 1,820 $ 1,095 $ 2,915 Cost of revenue 1,352 1,095 2,447 Gross profit $ 468 $ 0 $ 468 Three months ended September 30, 2014 Revenue $ 799 $ 789 $ 1,588 Cost of revenue 530 578 1,108 Gross profit $ 269 $ 211 $ 480 Nine months ended September 30, 2015 Revenue $ 3,590 $ 3,128 $ 6,718 Cost of revenue 2,482 2,863 5,345 Gross profit $ 1,108 $ 265 $ 1,373 Nine months ended September 30, 2014 Revenue $ 1,841 $ 2,006 $ 3,847 Cost of revenue 1,432 1,410 2,842 Gross profit $ 409 $ 596 $ 1,005
Schedule of Geographic Information	Three months e nded September 30, Nine months ended September 30, 2015 2014 2015 2014 North America $ 2,379 $ 1,271 $ 5,272 $ 3,102 Europe, Middle East, Asia 536 317 1,446 745 $ 2,915 $ 1,588 $ 6,718 $ 3,847

Organization (Details)

Organization (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Organization [Abstract]
Accumulated deficit	$ 86,746		$ 71,801
Cash	11,238	$ 7,176	$ 25,190	$ 805
Cash used in operations	13,082	$ 12,296
Average monthly net use of cash	$ 1,550

Basis of Presentation and Sum30

Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Details) - Customer [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Customer One [Member] | Accounts receivable [Member]
Concentration Risk [Line Items]
Concentration percentage			15.00%		22.00%
Customer One [Member] | Net sales [Member]
Concentration Risk [Line Items]
Concentration percentage	48.00%	19.00%	33.00%	17.00%
Customer Two [Member] | Accounts receivable [Member]
Concentration Risk [Line Items]
Concentration percentage			11.00%		11.00%
Customer Two [Member] | Net sales [Member]
Concentration Risk [Line Items]
Concentration percentage		17.00%
Customer Three [Member] | Accounts receivable [Member]
Concentration Risk [Line Items]
Concentration percentage			10.00%
Customer Three [Member] | Net sales [Member]
Concentration Risk [Line Items]
Concentration percentage		17.00%

The Merger, Offering and Othe31

The Merger, Offering and Other Related Transactions (Merger, Narrative) (Details)	9 Months Ended
	Sep. 30, 2015Rateshares
The Merger, Offering and Other Related Transactions [Abstract]
Common stock issued for acquisition	5,280,368
Previously held common stock issued for acquisition	4,500,600
Number of newly issued common stock issued for acquisition	779,768
Equity interest percentage	6.80%
Common stock [Member]
Business Acquisition [Line Items]
Shares issued in business acquisition	42,615,556
Conversion ratio | Rate	152.38%
Warrants [Member]
Business Acquisition [Line Items]
Shares issued in business acquisition	621,361
Stock options [Member]
Business Acquisition [Line Items]
Shares issued in business acquisition	7,602,408
Shares converted in business acquisition	4,989,111
Series A [Member]
Business Acquisition [Line Items]
Conversion ratio | Rate	162.90%
Series A-2 [Member]
Business Acquisition [Line Items]
Conversion ratio | Rate	195.48%
Series B [Member]
Business Acquisition [Line Items]
Conversion ratio | Rate	195.48%

The Merger, Offering and Othe32

The Merger, Offering and Other Related Transactions (Repayment of 2013 Bridge Note, Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Nov. 30, 2013	Sep. 30, 2015	Oct. 31, 2014
Repayment of 2013 Bridge Note [Line Items]
Number of shares called by warrants		36,055,000	30,300,000
Bridge Warrants [Member]
Repayment of 2013 Bridge Note [Line Items]
Number of warrants issued for conversion of debt	2,500,000
Exercise price	$ 1	$ 1
Expiration period	3 years	3 years
2013 Bridge Notes [Member]
Repayment of 2013 Bridge Note [Line Items]
Principal amount	$ 5,000
Accrued interest	$ 83	$ 5,083
Number of shares called by warrants	5,000,000

The Merger, Offering and Othe33

The Merger, Offering and Other Related Transactions (Private Placement Offering and Offer to Amend and Exercise, Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 06, 2014	Jan. 14, 2014	Nov. 30, 2013	Sep. 30, 2015	Sep. 30, 2014	Nov. 30, 2014	Oct. 31, 2014
Private Placement Offering [Line items]
Number of Units issued	9,720,000	20,580,000		30,300,000
Price per Unit	$ 1	$ 1		$ 1
Shares attached to each Unit	1	1		1
Warrants attached to each Unit	1	1		1
Repayment of senior note				$ 40	$ 2,547
Conversion price				$ 1
Payment of debt conversion and private placement commission				$ 3,030
Number of shares called by warrants				36,055,000			30,300,000
Bridge Warrants [Member]
Private Placement Offering [Line items]
Exercise price			$ 1	$ 1
Expiration period			3 years	3 years
PPO warrants [Member]
Private Placement Offering [Line items]
Exercise price				$ 2		$ 2
Expiration period				5 years
Number of shares called by warrants						22,755,500
PPO warrants [Member] | Offer to Amend and Exercise [Member]
Private Placement Offering [Line items]
Exercise price						$ 1
Bridge Agent Warrants [Member]
Private Placement Offering [Line items]
Exercise price				$ 1
Number of shares called by warrants				3,030,000
PPO Agent Warrants [Member]
Private Placement Offering [Line items]
Expiration period				5 years
2013 Bridge Notes [Member]
Private Placement Offering [Line items]
Gross proceeds				$ 25,300
Debt and accrued interest			$ 83	5,083
Repayment of senior note				2,553
Payment of offering costs				$ 3,338
Number of shares called by warrants			5,000,000

The Merger, Offering and Othe34

The Merger, Offering and Other Related Transactions (2014 Equity Incentive Plan, Narrative) (Details) - shares	Jun. 10, 2015	Sep. 30, 2015	Jan. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive shares authorized		14,410,000
Equity Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive shares authorized		26,000,000	14,410,000
Options granted		3,332,800
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	11,590,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		11,801,901
Conversion [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted		7,602,408
Merger [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted		2,300,000

Deferred Revenues (Details)

Deferred Revenues (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Deferred Revenue Arrangement [Line Items]
Deferred revenues	$ 8,238	$ 7,307
Less current portion	(3,839)	(3,412)
Deferred revenues, non-current	4,399	3,895
Deferred Ekso medical device costs	4,344	3,568
Less current portion	(1,920)	(1,551)
Deferred cost of revenue, non-current	2,424	2,017
Customer deposits and advances [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenues	90	105
Deferred Ekso medical device revenues [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenues	5,917	5,327
Deferred service and leasing revenues [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenues	$ 2,231	$ 1,875

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Accrued Liabilities [Abstract]
Salaries, benefits and related expenses	$ 1,687	$ 1,847
Professional fees	$ 298	184
Warranty expense		126
Taxes	$ 46	46
Royalties		50
Travel	$ 15	76
All Other	144	49
Total	$ 2,190	$ 2,378

Capital Lease Obligation (Narra

Capital Lease Obligation (Narrative) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Other Notes Payable [Member]
Debt Instrument [Line Items]
Principal outstanding	$ 200
Stated interest rate	7.00%
Maturity date	May 31, 2017
Minimum monthly payments	$ 4
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
Principal outstanding	$ 166
Stated interest rate	4.70%
Maturity date	Jul. 1, 2020
Minimum monthly payments	$ 3

Capital Lease Obligation (Sched

Capital Lease Obligation (Schedule of future obligations under debt instruments) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Future obligations under debt instruments
2015 (remainder)	$ 22
2,016	90
2,017	60
2,018	37
2,019	37
Thereafter	22
Total minimum payments	268
Less: interest	(24)
Present value minimum payments	244	$ 13
Less: current portion	(79)	$ (41)
Long-term portion of capital lease obligation	165
Capital Lease [Member]
Future obligations under debt instruments
2015 (remainder)	10
2,016	42
2,017	40
2,018	37
2,019	37
Thereafter	22
Total minimum payments	188
Less: interest	(19)
Present value minimum payments	169
Less: current portion	(35)
Long-term portion of capital lease obligation	134
Leasehold Improvement Note [Member]
Future obligations under debt instruments
2015 (remainder)	12
2,016	48
2,017	$ 20
2,018
2,019
Thereafter
Total minimum payments	$ 80
Less: interest	(5)
Present value minimum payments	75
Less: current portion	(44)
Long-term portion of capital lease obligation	$ 31

Operating Lease (Details)

Operating Lease (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Operating Lease [Abstract]
Expiration date			May 31, 2017
Option to renew			5 years
Future minimum operating lease payments:
2015 (remainder of year)	$ 94		$ 94
2,016	375		375
2,017	157		157
Total	626		626
Rent expense	$ 86	$ 86	$ 258	$ 257

Capitalization and Equity Str40

Capitalization and Equity Structure (Details) - shares	Sep. 30, 2015	Dec. 31, 2014
Capitalization and Equity Structure [Abstract]
Common stock, shares authorized	500,000,000	500,000,000
Convertible Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	102,371,591	101,621,358
Common stock, shares outstanding	102,371,591	101,621,358
Convertible Preferred stock, shares issued	0	0
Convertible Preferred stock, shares outstanding	0	0

Warrants (Narrative) (Details)

Warrants (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Oct. 31, 2014
Class of Stock [Line Items]
Warrant Shares Issued	36,055,000		36,055,000		30,300,000
Gain (loss) on warrant liability		$ 15,773		$ (1,206)
Warrants [Member]
Class of Stock [Line Items]
Exercise price					$ 2
Offer To Amend And Exercise [Member]
Class of Stock [Line Items]
Gain (loss) on warrant liability		$ (15,773)		$ 1,206
Offer To Amend And Exercise [Member] | Warrants [Member]
Class of Stock [Line Items]
Exercise price					$ 1

Warrants (Schedule of Assumptio

Warrants (Schedule of Assumption Used in Valuation) (Details) - Warrants [Member]	9 Months Ended
	Sep. 30, 2014item$ / shares
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Dividend yield
Share price at final valuation	$ 0.84
Periods in the model | item	10
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	0.72%
Expected term	2 years 3 months 18 days
Volatility	65.00%
Periodic rate	0.17%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.53%
Expected term	4 years 3 months 18 days
Volatility	70.00%
Periodic rate	0.66%

Warrants (Schedule of Warrants

Warrants (Schedule of Warrants Outstanding) (Details) - $ / shares		1 Months Ended	9 Months Ended
		Nov. 30, 2013	Sep. 30, 2015	Nov. 30, 2014
Class of Warrant or Right [Line Items]
Balance			13,795,861
Exercised			(51,420)
Balance			13,744,441
Placement agent warrants [Member]
Class of Warrant or Right [Line Items]
Balance			3,030,000
Exercise price			$ 1
Warrant term			5 years
Exercised			(48,700)
Balance			2,981,300
Bridge warrants [Member]
Class of Warrant or Right [Line Items]
Balance			2,600,000
Exercise price		$ 1	$ 1
Warrant term		3 years	3 years
Balance			2,600,000
PPO warrants [Member]
Class of Warrant or Right [Line Items]
Balance			7,544,500
Exercise price			$ 2	$ 2
Warrant term			5 years
Balance			7,544,500
Pre-Merger/PPO warrants [Member]
Class of Warrant or Right [Line Items]
Balance	[1]		621,361
Exercise price	[1]		$ 1.38
Exercised	[1]		(2,720)
Balance	[1]		618,641
Expiration date			May 20, 2023
[1]	The Pre-Merger/PPO warrants all expire on May 20, 2023.

Stock-based Compensation Plan44

Stock-based Compensation Plans and Awards (Narrative) (Details) - USD ($) $ in Thousands	Jun. 10, 2015	Sep. 30, 2015	Jan. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive shares authorized		14,410,000
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercised on a cashless basis		846,576
Shares withheld to cover amount of cashless exercise		368,993
Unrecognized compensation cost		$ 4,998
Unrecognized compensation cost, period for recognition		2 years 11 months 5 days
Equity Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive shares authorized		26,000,000	14,410,000
Conversion of prior plan shares		7,602,408
Vesting period		4 years
Additional shares authorized for grant	11,590,000
Total shares available		11,801,901
Minimum [Member] | Equity Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair market value		100.00%
Minimum [Member] | Stockholders [Member] | Equity Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair market value		110.00%
Maximum [Member] | Equity Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period		10 years
Maximum [Member] | Stockholders [Member] | Equity Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period		5 years

Stock-based Compensation Plan45

Stock-based Compensation Plans and Awards (Summary of Stock Option Activity) (Details) - 2014 Plan [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Stock Awards
Balance as of December 31, 2014 | shares	10,791,081
Options granted | shares	3,332,800
Options exercised | shares	(1,067,806)
Options forfeited | shares	(128,888)
Options cancelled | shares	(104,813)
Balance as of September 30, 2015 | shares	12,822,374
Vested and expected to vest at September 30, 2015 | shares	11,850,532
Exercisable as of September 30, 2015 | shares	6,103,793
Weighted-Average Exercise Price
Balance as of December 31, 2014	$ 0.79
Options granted	1.40
Options exercised	0.52
Options forfeited	0.76
Options cancelled	0.50
Balance as of September 30, 2015	0.98
Vested and expected to vest at September 30, 2015	0.95
Exercisable as of September 30, 2015	$ 0.66
Weighted-Average Remaining Contractual Life (Years)
Balance as of September 30, 2015	7 years 10 months 2 days
Vested and expected to vest at September 30, 2015	7 years 8 months 23 days
Exercisable as of September 30, 2015	6 years 6 months 4 days
Aggregate Intrinsic Value
Balance as of September 30, 2015 | $	$ 4,154
Vested and expected to vest at September 30, 2015 | $	4,098
Exercisable as of September 30, 2015 | $	$ 3,498

Stock-based Compensation Plan46

Stock-based Compensation Plans and Awards (Schedule of Fair Value Calculation Assumptions) (Details)	3 Months Ended			9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	[1]	Sep. 30, 2015	Sep. 30, 2014
Assumptions used for calculation of fair value per share
Dividend yield
Risk-free interest rate	1.68%
Risk-free interest rate, minimum				1.41%	1.74%
Risk-free interest rate, maximum				2.50%	2.61%
Expected term	6 years 29 days
Volatility	75.27%
Volatility, minimum				73.21%	65.66%
Volatility, maximum				75.27%	66.46%
Minimum [Member]
Assumptions used for calculation of fair value per share
Expected term				6 years 29 days	6 years 29 days
Maximum [Member]
Assumptions used for calculation of fair value per share
Expected term				10 years	10 years
[1]	No options were granted for the three months ended September 30, 2014.

Stock-based Compensation Plan47

Stock-based Compensation Plans and Awards (Schedule of Stock-based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 467	$ 117	$ 1,259	$ 810
Sales and Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	147	9	440	260
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	133	36	295	125
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 187	$ 72	$ 524	$ 425

Income Taxes (Details)

Income Taxes (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Income Taxes [Abstract]
Change in unrecognized tax benefit
Expected significant changes to unrecognized tax benefits

Commitments and Contingencies (

Commitments and Contingencies (Details) - Royalty Agreement Terms [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Future minimum annual royalties
2,016	$ 50
Net sales [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage	1.00%
License fees [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage	21.00%
Sub-licensee net sales [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage	1.00%

Net Income (Loss) Per Share (Sc

Net Income (Loss) Per Share (Schedule of Basic and Diluted Net Income (Loss) Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Numerator:
Net profit (loss)	$ (5,185)	$ 12,024	$ (14,945)	$ (13,614)
Adjustment for change in fair value of warrant liability		(15,773)
Diluted	$ (5,185)	$ (3,749)	$ (14,945)	$ (13,614)
Denominator: Weighted-average common shares outstanding used in computing basic and diluted net income (loss) per share
Basic	102,239,868	78,513,144	102,043,392	74,943,169
Dilutive effect of warrants		750,653
Dilutive effect of stock options		4,072,574
Diluted	102,239,868	83,336,371	102,043,392	74,943,169
Net income (loss) per share, basic	$ (0.05)	$ 0.15	$ (0.15)	$ (0.18)
Net income (loss) per share, diluted	$ (0.05)	$ (0.04)	$ (0.15)	$ (0.18)

Net Income (Loss) Per Share (51

Net Income (Loss) Per Share (Schedule of Antidilutive Securities) (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	26,566,815		26,566,815	12,131,613
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	12,822,374		12,822,374	3,724,529
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	13,744,441		13,744,441	8,407,084

Segment Disclosures (Schedule o

Segment Disclosures (Schedule of Segment Reporting Information) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Revenue	$ 2,915	$ 1,588	$ 6,718	$ 3,847
Cost of revenue	2,447	1,108	5,345	2,842
Gross profit	468	480	1,373	1,005
Engineering Services [Member]
Segment Reporting Information [Line Items]
Revenue	1,820	799	3,590	1,841
Cost of revenue	1,352	530	2,482	1,432
Gross profit	468	269	1,108	409
Medical Devices [Member]
Segment Reporting Information [Line Items]
Revenue	1,095	789	3,128	2,006
Cost of revenue	1,095	578	2,863	1,410
Gross profit	$ 0	$ 211	$ 265	$ 596

Segment Disclosures (Schedule53

Segment Disclosures (Schedule of Geographic Information) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 2,915	$ 1,588	$ 6,718	$ 3,847
North America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	2,379	1,271	5,272	3,102
Europe, Middle East, Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 536	$ 317	$ 1,446	$ 745